Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to 30 peptide sequences and their variants derived from HLA class I and class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.
Type:
Grant
Filed:
August 2, 2016
Date of Patent:
February 2, 2021
Assignee:
IMMATICS BIOTECHNOLOGIES GMBH
Inventors:
Toni Weinschenk, Oliver Schoor, Claudia Trautwein, Norbert Hilf, Steffen Walter, Harpreet Singh
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Type:
Grant
Filed:
September 11, 2020
Date of Patent:
January 26, 2021
Assignee:
IMMATICS BIOTECHNOLOGIES GMBH
Inventors:
Toni Weinschenk, Jens Fritsche, Harpreet Singh, Andrea Mahr, Martina Ott, Claudia Wagner, Oliver Schoor
Abstract: The present invention described herein relates to molecules and compositions that interact with molecules that suppress the immune system. More specifically, embodiments described herein concern the discovery, manufacture, and use of compositions that remove immunosuppression the immune system by binding to immunoregulatory peptides that interact with receptors on immune cells, compositions that can stimulate immune cells, and compositions that are cytotoxic to tumor cells.
Abstract: The present invention relates to chimeric antigen receptors (CAR). CARs are able to redirect immune cell specificity and reactivity toward a selected target exploiting the ligand-binding domain properties. In particular, the present invention relates to a Chimeric Antigen Receptor in which extracellular ligand binding is a scFV derived from a CD19 monoclonal antibody, preferably 4G7. The present invention also relates to polynucleotides, vectors encoding said CAR and isolated cells expressing said CAR at their surface. The present invention also relates to methods for engineering immune cells expressing 4G7-CAR at their surface which confers a prolonged “activated” state on the transduced cell. The present invention is particularly useful for the treatment of B-cells lymphomas and leukemia.
Type:
Grant
Filed:
May 12, 2014
Date of Patent:
December 29, 2020
Assignee:
Cellectis
Inventors:
Roman Galetto, Julianne Smith, Andrew Scharenberg, Cécile Schiffer-Mannioui
Abstract: The present invention relates to a bispecific antibody construct comprising a first binding domain which binds to human CD70 on the surface of a target cell and a second binding domain which binds to human CD3 on the surface of a T cell. Moreover, the invention provides a polynucleotide encoding the antibody construct, a vector comprising said polynucleotide and a host cell transformed or transfected with said polynucleotide or vector. Furthermore, the invention provides a process for the production of the antibody construct of the invention, a medical use of said antibody construct and a kit comprising said antibody construct.
Type:
Grant
Filed:
August 1, 2016
Date of Patent:
December 1, 2020
Assignees:
AMGEN RESEARCH (MUNICH) GMBH, AMGEN INC.
Inventors:
Tobias Raum, Claudia Blümel, Wibke Deisting, Patrick Hoffmann, Ralf Lutterbüse, Elisabeth Nahrwold, Olivier Nolan-Stevaux, Marc Panzer
Abstract: Disclosed herein are PSMA binding proteins with improved binding affinities, and robust aggregation profiles. Also described are multispecific binding proteins comprising a PSMA binding protein according to the instant disclosure. Pharmaceutical compositions comprising the binding proteins disclosed herein and methods of using such formulations are further provided.
Type:
Grant
Filed:
November 22, 2017
Date of Patent:
December 1, 2020
Assignee:
HARPOON THERAPEUTICS, INC.
Inventors:
Robert Dubridge, Pui Seto, Patrick Baeuerle, Jeanmarie Guenot, Holger Wesche, Bryan D. Lemon, Richard J. Austin
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Type:
Grant
Filed:
June 24, 2020
Date of Patent:
November 24, 2020
Assignee:
IMMATICS BIOTECHNOLOGIES GMBH
Inventors:
Andrea Mahr, Toni Weinschenk, Anita Wiebe, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
Abstract: Provided herein are isolated CD3×PSMA-bispecific antigen-binding molecules or bispecific antigen-binding fragment thereof wherein a FN3 domain specifically binds human prostate specific membrane antigen (PSMA) and a second antigen-binding site immunospecifically binds CD3. Also described are fusion proteins and related polynucleotides capable of encoding the provided fusion proteins and, cells expressing the provided fusion proteins. In addition, methods of using the provided isolated CD3×PSMA-bispecific antigen-binding molecules or bispecific antigen-binding fragment thereof are described.
Type:
Grant
Filed:
May 6, 2016
Date of Patent:
November 24, 2020
Assignee:
Janssen Biotech, Inc.
Inventors:
Glenn Anderson, Rosa Cardoso, Michael Diem, Francois Gaudet, Shalom Goldberg, Benjamin Harman, Linus Hyun, Steven Jacobs, Donna Klein, Yingzhe Li, Jinquan Luo, Ronan McDaid, Jill Mooney, Jennifer Nemeth-Seay, Karyn O'Neil, Steven Pomerantz, Galla Chandra Rao, Tracy Spinka-Doms, Alexey Teplyakov, Leopoldo Luistro, Sheng-Jiun Wu
Abstract: Provided herein are prostate specific membrane antigen (PSMA) targeting trispecific proteins comprising a domain binding to CD3, a half-life extension domain, and a domain binding to PSMA. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such PSMA targeting trispecific proteins. Also disclosed are methods of using the disclosed PSMA targeting trispecific proteins in the prevention, and/or treatment diseases, conditions and disorders.
Type:
Grant
Filed:
November 22, 2017
Date of Patent:
November 24, 2020
Assignee:
HARPOON THERAPEUTICS, INC.
Inventors:
Patrick Baeuerle, Jeanmarie Guenot, Holger Wesche, Robert B. Dubridge, Bryan D. Lemon, Richard J. Austin, Pui Seto
Abstract: PSMA binding FN3 domains, their conjugates, isolated nucleotides encoding the molecules, vectors, host cells, and methods of making thereof are useful in the generation of therapeutic molecules and treatment and diagnosis of diseases and disorders.
Type:
Grant
Filed:
May 6, 2016
Date of Patent:
November 24, 2020
Assignee:
Janssen Biotech, Inc.
Inventors:
Rosa Cardoso, Michael Diem, Shalom Goldberg, Linus Hyun, Steven Jacobs, Donna Klein, Karyn O'Neil, Tracy Spinka-Doms
Abstract: A method is described of localizing an intact immunoglobulin-format antibody in cytosol by permeating the cell membrane, thereby avoiding the necessity to use a special external protein delivery system. The method achieves high effects on the treatment and diagnosis of tumor and disease-related factors that show structurally complex interactions through a wide and flat surface between protein and protein.
Type:
Grant
Filed:
July 22, 2015
Date of Patent:
November 24, 2020
Assignee:
ORUM THERAPEUTICS INC.
Inventors:
Yong-Sung Kim, Dong-Ki Choi, Seung-Min Shin, Sung-Hoon Kim
Abstract: This invention provides antibodies or functional fragments thereof that bind to PD-1 with high affinity. The invention provides nucleic acid molecules encoding the antibodies or the fragments thereof according to the present invention, expression vectors and host cells for expressing the antibodies or the functional fragments thereof according to the present invention, as well as methods for producing the antibodies or the functional fragments thereof according to the present invention. The present invention also provides immunoconjugates and pharmaceutical compositions comprising the antibodies or the functional fragments thereof according to the present invention. The present invention additionally provides methods for treating a plurality of diseases (comprising cancers, infectious diseases and inflammatory diseases) by using the antibodies or the functional fragments thereof disclosed herein.
Abstract: The invention relates to new anti-hCTLA-4 antibodies that bind to a different epitope than prior art anti-CTLA4 antibodies, methods to produce these antibodies and therapeutic and diagnostic uses of these antibodies. These antibodies show a similar affinity for the CTLA4 antigen and they are also able to block the binding of CTLA4 to CD80 and/or CD86.
Type:
Grant
Filed:
October 2, 2017
Date of Patent:
October 20, 2020
Assignee:
ADURO BIOTECH HOLDINGS, EUROPE B.V.
Inventors:
Hans Van Eenennaam, Andrea Van Elsas, Joost Kreijtz, David Lutje Hulsik, Paul Vink
Abstract: The invention relates to HER3/HER2 bispecific antibodies binding to the beta-hairpin of HER3 and domain II of HER2, their preparation and use as medicament.
Type:
Grant
Filed:
November 10, 2016
Date of Patent:
October 20, 2020
Assignee:
HOFFMANN-LA ROCHE INC.
Inventors:
Birgit Bossenmaier, Richard Buick, Stefan Dengl, Michael Gerg, Carmen Peess, Wolfgang Schaefer, Michael Schraeml, Claudio Sustmann
Abstract: The present invention relates to a selectively soluble polymer capable of binding to one or more constituents in a mixture containing various biological materials and the methods of using such a polymer to purify a biomolecule from such a mixture. The polymer is soluble in the mixture under a certain set of process conditions such as pH or temperature and is rendered insoluble and precipitates out of solution upon a change in the process conditions. While in its solubilized state, the polymer is capable of binding to a selected entity within the stream such as impurities (DNA, RNA, host cell protein, endotoxins, etc.) in a cell broth and remains capable of binding to that entity even after the polymer is precipitated out of solution. The precipitate can then be filtered out from the remainder of the stream and the desired biomolecule is recovered and further processed.
Abstract: Provided herein are, inter alia, anti-CD73 antibodies and methods of using the same. The antibodies provided include amino acid substitution embodiments affecting the antibody glycosylation state. The antibodies provided herein are, inter alia, useful for the treatment of cancer and effective for inhibition of CD73 activity.
Type:
Grant
Filed:
July 11, 2017
Date of Patent:
October 6, 2020
Assignee:
CORVUS PHARMACEUTICALS, INC.
Inventors:
Emily Piccione Griffin, Richard A. Miller, Ian McCaffery
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Type:
Grant
Filed:
April 17, 2020
Date of Patent:
October 6, 2020
Assignee:
Immatics Biotechnologies GmbH
Inventors:
Toni Weinschenk, Jens Fritsche, Harpreet Singh, Andrea Mahr, Martina Ott, Claudia Wagner, Oliver Schoor
Abstract: The present invention provides bispecific antibody constructs of a specific Fc modality characterized by comprising a first domain binding to PSMA, a second domain binding to an extracellular epitope of the human and the Macaca CD3? chain and a third domain, which is the specific Fc modality. Moreover, the invention provides a polynucleotide, encoding the antibody construct, a vector comprising this polynucleotide, host cells, expressing the construct and a pharmaceutical composition comprising the same.
Type:
Grant
Filed:
February 2, 2017
Date of Patent:
September 22, 2020
Assignee:
AMGEN RESEARCH (MUNICH) GMBH
Inventors:
Tobias Raum, Markus Münz, Johannes Brozy, Peter Kufer, Patrick Hoffmann, Matthias Friedrich, Benno Rattel, Pamela Bogner, Andreas Wolf, Cornelius Pompe
Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Type:
Grant
Filed:
April 17, 2020
Date of Patent:
September 22, 2020
Assignee:
IMMATICS BIOTECHNOLOGIES GMBH
Inventors:
Andrea Mahr, Toni Weinschenk, Anita Wiebe, Colette Song, Oliver Schoor, Jens Fritsche, Harpreet Singh
Abstract: The present disclosure relates to a multispecific molecule comprising a binding domain specific to the antigen CD45 and a binding domain specific to the antigen CD79a and/or CD79b, compositions comprising same and use of each in treatment, for example treatment of autoimmune disease.
Type:
Grant
Filed:
July 16, 2015
Date of Patent:
September 15, 2020
Assignee:
UCB BIOPHARMA SPRL
Inventors:
Helene Margaret Finney, Stephen Edward Rapecki, Michael John Wright, Kerry Louise Tyson